CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism

Summary

This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent hypoglycemia with lower intravenous glucose infusion rates in children \< 1 year of age with congenital hyperinsulinism.

Timeline

Start

2016-10

Primary completion

2018-09

Completion

2018-10

Drugs

Indications